Tags |
|
|
Links |
|
|
Answer You - Low Dose Naltrexone Treatment in Multiple Sclerosis
There is a certain law of the universe that goes something like this. It doesn't matter how fast your computer is when it leaves the store, when you get it home and use it for a little while it will start to run really slow. In fact, that is probably one of the largest complaints that we hear when people bring us their computers. The conversation with them usually begins with the sentence “My computer is running really slow” and we go from there.What is it
Proponents of LDN treatment indicate that LDN does not work when taken in conjunction with beta interferon, a standard MS treatment. There does not seem to be interference with glatiramer acetate. Neither piece of information has any medical or scientific proof yet.
Where does that leave us?
At this point, since LDN is not a proven treatment, it would be poor medic
Computer network training is one of the latest gateways to jump into the competitive IT world. Network is a media for computers to communicate with each other by sending files, instant messages and other information. This is accomplished through LAN (Local Area Network) and WAN (Wide Area Network). Nowadays, many companies use networks of computers to run their operations smoothly. So, computer networking is a good job option. Basically, there are two main network
Naltrexone is an opioid antagonist (it binds to opioid receptors in the brain without causing opioid effects). It is used in treatment of addictions to opioids and alcohol, and is FDA approved for such uses. Doses for addiction treatment are typically 50 - 150 mg a day for three days a week. At much lower doses of typically 3 to 4.5 mg daily, Naltrexone has been prescribed for various autoimmune disorders, including MS and ALS (amyotrophic lateral sclerosis). Thus the term Low Dose Naltrexone, or LDN.
A recent study of LDN treatment in Crohn's disease was published by Smith et al (Am J Gastroenterol 2007;102:1–9) that showed that LDN was effective and safe in the treatment of Crohn's disease.
The bad news
The bad news is that currently there is no clinical proof that low dose naltrexone aids in the treatment of multiple sclerosis. There have been no clinical trials, data is not being gathered by prescribing physicians, and some prescribing physicians are not even consulting with patients' neurologists or general practitioners.
The good news
There is currently an online petition to garner support for proper clinical trials of Low Dose Naltrexone at www.thepetitionsite.com . Everyone agrees that there is solid reason for proper clinical trials. Often when results are only anecdotal, they miss the big picture of what happens when large populations are treated with a medication. In scientific language, this is known as a study having enough "power" to stand up to statistical analysis.
What's the buzz?
The buzz suggests that LDN reduces the frequency of MS relapses, and even halts the progression of the disease. That's big news in a world where patients at best have a few treatment options with possible heavy side effects and little to no hope that those treatments will halt the disease.
At http://www.ldners.org/, there are at least two self-reported surveys of LDN users. The site is also a great resource for finding the latest news in LDN treatment of MS, and the progress of the funding and implementation of clinical trials. Soon there should be some reliable clinical data, thanks largely to the activity of MS patients themselves.
The one article by Y.P. Agrawal in a peer reviewed journal (Medical Hypothesis 2005, 64, 721-724) presents a hypothesis of how naltrexone may possibly help in MS treatment. Essentially his hypothesis is that naltrexone could help in fighting the death of oligodendrocytes, the cells that manufacture myelin. A clinical trial could help further or disprove his hypothesis.
Proponents of LDN treatment indicate that LDN does not work when taken in conjunction with beta interferon, a standard MS treatment. There does not seem to be interference with glatiramer acetate. Neither piece of information has any medical or scientific proof yet.
Where does that leave us?
At this point, since LDN is not a proven treatment, it would be poor medica
Forex is a foreign-exchange currency market, where investors from all over the world buy and sell different currency pairs. The development of the Internet and computer programs have made it possible for people from all over the world to enter this multi-billion dollar market. But, most of them get caught up by the system. Start-ups with as much as $250 in their account are highly-likely to fail. If you want to invest in this market, you need a strategy. The goal
The bad news
The bad news is that currently there is no clinical proof that low dose naltrexone aids in the treatment of multiple sclerosis. There have been no clinical trials, data is not being gathered by prescribing physicians, and some prescribing physicians are not even consulting with patients' neurologists or general practitioners.
The good news
There is currently an online petition to garner support for proper clinical trials of Low Dose Naltrexone at www.thepetitionsite.com . Everyone agrees that there is solid reason for proper clinical trials. Often when results are only anecdotal, they miss the big picture of what happens when large populations are treated with a medication. In scientific language, this is known as a study having enough "power" to stand up to statistical analysis.
What's the buzz?
The buzz suggests that LDN reduces the frequency of MS relapses, and even halts the progression of the disease. That's big news in a world where patients at best have a few treatment options with possible heavy side effects and little to no hope that those treatments will halt the disease.
At http://www.ldners.org/, there are at least two self-reported surveys of LDN users. The site is also a great resource for finding the latest news in LDN treatment of MS, and the progress of the funding and implementation of clinical trials. Soon there should be some reliable clinical data, thanks largely to the activity of MS patients themselves.
The one article by Y.P. Agrawal in a peer reviewed journal (Medical Hypothesis 2005, 64, 721-724) presents a hypothesis of how naltrexone may possibly help in MS treatment. Essentially his hypothesis is that naltrexone could help in fighting the death of oligodendrocytes, the cells that manufacture myelin. A clinical trial could help further or disprove his hypothesis.
Proponents of LDN treatment indicate that LDN does not work when taken in conjunction with beta interferon, a standard MS treatment. There does not seem to be interference with glatiramer acetate. Neither piece of information has any medical or scientific proof yet.
Where does that leave us?
At this point, since LDN is not a proven treatment, it would be poor medic
Most of us do not realize that we can get paid to fill out surveys. Consumers are looking for the opportunity to share their insights with major corporations and these major corporations want consumer inputs to be assimilated into their products as it assists in marketing and product design. There is no point in designing a fish-flavored cough syrup in plastic bags if nobody is going to buy it.That type of critical business error can end up costing millions
What's the buzz?
The buzz suggests that LDN reduces the frequency of MS relapses, and even halts the progression of the disease. That's big news in a world where patients at best have a few treatment options with possible heavy side effects and little to no hope that those treatments will halt the disease.
At http://www.ldners.org/, there are at least two self-reported surveys of LDN users. The site is also a great resource for finding the latest news in LDN treatment of MS, and the progress of the funding and implementation of clinical trials. Soon there should be some reliable clinical data, thanks largely to the activity of MS patients themselves.
The one article by Y.P. Agrawal in a peer reviewed journal (Medical Hypothesis 2005, 64, 721-724) presents a hypothesis of how naltrexone may possibly help in MS treatment. Essentially his hypothesis is that naltrexone could help in fighting the death of oligodendrocytes, the cells that manufacture myelin. A clinical trial could help further or disprove his hypothesis.
Proponents of LDN treatment indicate that LDN does not work when taken in conjunction with beta interferon, a standard MS treatment. There does not seem to be interference with glatiramer acetate. Neither piece of information has any medical or scientific proof yet.
Where does that leave us?
At this point, since LDN is not a proven treatment, it would be poor medic
1. Keep it Simple!These are probably the best words of advice, and it ties into almost all of our upcoming tips. A complicated logo will not only make your logo difficult to reproduce and maintain, but you will also fail to engage your audience. The logo is the ultimate ‘elevator’ pitch to your potential clients and business partners. You don’t have time to recite your entire business plan in an elevator pitch, and the same concept applies
At http://www.ldners.org/, there are at least two self-reported surveys of LDN users. The site is also a great resource for finding the latest news in LDN treatment of MS, and the progress of the funding and implementation of clinical trials. Soon there should be some reliable clinical data, thanks largely to the activity of MS patients themselves.
The one article by Y.P. Agrawal in a peer reviewed journal (Medical Hypothesis 2005, 64, 721-724) presents a hypothesis of how naltrexone may possibly help in MS treatment. Essentially his hypothesis is that naltrexone could help in fighting the death of oligodendrocytes, the cells that manufacture myelin. A clinical trial could help further or disprove his hypothesis.
Proponents of LDN treatment indicate that LDN does not work when taken in conjunction with beta interferon, a standard MS treatment. There does not seem to be interference with glatiramer acetate. Neither piece of information has any medical or scientific proof yet.
Where does that leave us?
At this point, since LDN is not a proven treatment, it would be poor medic
Would it really shock you if I said that our US government could be doing a better job of managing our funds and performing various functions? Fema’s (the Federal Emergency Management Agency) handling of the Katrina Hurricane disaster is just one example of how it is completely inept when it comes to unexpected events. It also filters down to a local level as well. Funds that were meant to be used to reinforce the levies before Katrina were spent on the casinos. T
Proponents of LDN treatment indicate that LDN does not work when taken in conjunction with beta interferon, a standard MS treatment. There does not seem to be interference with glatiramer acetate. Neither piece of information has any medical or scientific proof yet.
Where does that leave us?
At this point, since LDN is not a proven treatment, it would be poor medical advice to discontinue a treatment that is working for an MS patient. Patients should be encouraged to join the clinical trials if they are able. Patients and advocates should continue to push for proper testing and aid in the fund raising for proper research of LDN treatment of MS.
If you are an MS patient, you should always listen to your neurologist and general practitioner. Discuss the latest LDN news with them and ask what they recommend. Soon there should be more information available for your medical practitioners to make educated decisions about your treatment and LDN therapy.
HTTP = HTML link (for blogs, profiles,phorums):
<a href="http://www.answeryou.net/article/241952/answeryou-Low-Dose-Naltrexone-Treatment-in-Multiple-Sclerosis.html">Low Dose Naltrexone Treatment in Multiple Sclerosis</a>
BB link (for phorums):
[url=http://www.answeryou.net/article/241952/answeryou-Low-Dose-Naltrexone-Treatment-in-Multiple-Sclerosis.html]Low Dose Naltrexone Treatment in Multiple Sclerosis[/url]
Related Articles:
MySpace for Your Small Business - It's Not Just for Teenagers Anymore!
The Best and Fastest Way to Get Unlimited Free Back Links Guaranteed!
Most of My Peers Are Wrong About Investing in China
Bookmark it:
|